Castle Biosciences, Inc.
CSTL
$18.63
-$0.41-2.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -4.90% | 0.81% | -3.19% | -0.94% | 20.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.90% | 0.81% | -3.19% | -0.94% | 20.57% |
| Cost of Revenue | 25.33% | 13.17% | 19.83% | 21.40% | 17.91% |
| Gross Profit | -11.81% | -2.04% | -8.31% | -5.41% | 21.20% |
| SG&A Expenses | 10.71% | 13.54% | 10.71% | 13.66% | 20.88% |
| Depreciation & Amortization | -72.94% | -47.56% | 0.18% | -12.73% | 266.04% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.54% | 10.43% | 11.33% | 10.30% | 22.14% |
| Operating Income | -135.14% | -194.49% | -233.96% | -184.82% | -43.08% |
| Income Before Tax | 45.14% | -134.42% | -104.66% | -101.81% | -955.48% |
| Income Tax Expenses | 125.77% | 77.60% | -98.09% | -351.26% | -1,040.00% |
| Earnings from Continuing Operations | 43.82% | -124.32% | -122.08% | -49.29% | -920.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.82% | -124.32% | -122.08% | -49.29% | -920.05% |
| EBIT | -135.14% | -194.49% | -233.96% | -184.82% | -43.08% |
| EBITDA | -888.56% | -100.51% | -113.60% | -110.01% | 186.16% |
| EPS Basic | 46.22% | -123.31% | -121.10% | -51.53% | -879.93% |
| Normalized Basic EPS | -231.44% | -111.23% | -145.67% | -116.10% | -83.22% |
| EPS Diluted | 46.22% | -125.31% | -125.00% | -51.61% | -879.93% |
| Normalized Diluted EPS | -231.44% | -112.06% | -148.21% | -116.38% | -83.22% |
| Average Basic Shares Outstanding | 4.47% | 4.29% | 4.43% | 4.59% | 4.09% |
| Average Diluted Shares Outstanding | 4.47% | -2.87% | -1.12% | 2.81% | 4.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |